| 000 | 01680 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250513102431.0 | ||
| 264 | 0 | _c19961120 | |
| 008 | 199611s 0 0 eng d | ||
| 022 | _a0039-6060 | ||
| 024 | 7 |
_a10.1016/s0039-6060(96)80022-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKnechtle, S J | |
| 245 | 0 | 0 |
_aImpact of improving immunosuppressive treatment on outcome in cadaveric kidney transplantation. _h[electronic resource] |
| 260 |
_bSurgery _cOct 1996 |
||
| 300 |
_a719-24 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 |
_aAntilymphocyte Serum _xtherapeutic use |
| 650 | 0 | 4 | _aCadaver |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aCyclosporine _xtherapeutic use |
| 650 | 0 | 4 | _aDemography |
| 650 | 0 | 4 | _aEvaluation Studies as Topic |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGraft Rejection _xprevention & control |
| 650 | 0 | 4 |
_aGraft Survival _xdrug effects |
| 650 | 0 | 4 | _aHistocompatibility Testing |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aKidney Transplantation |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMuromonab-CD3 _xtherapeutic use |
| 650 | 0 | 4 |
_aMycophenolic Acid _xanalogs & derivatives |
| 650 | 0 | 4 | _aTissue Donors |
| 650 | 0 | 4 | _aTransplantation, Homologous |
| 700 | 1 | _aHeisey, D M | |
| 700 | 1 | _aPirsch, J D | |
| 700 | 1 | _aD'Alessandro, A M | |
| 700 | 1 | _aKalayoglu, M | |
| 700 | 1 | _aSollinger, H W | |
| 773 | 0 |
_tSurgery _gvol. 120 _gno. 4 _gp. 719-24 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0039-6060(96)80022-5 _zAvailable from publisher's website |
| 999 |
_c8855195 _d8855195 |
||